1-[1-(1-Adamantyl)ethoxy]-1-morpholin-4-ylpropan-2-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1-[1-(1-Adamantyl)ethoxy]-1-morpholin-4-ylpropan-2-ol
• 英文别名: 1-[1-(1-adamantyl)ethoxy]-1-morpholin-4-ylpropan-2-ol
• 化学式: C₁₉H₃₃NO₃
• 分子量: 323.5
• InChiKey: SJXDWLWLADEEIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL COMPOSITION OF 1-ADAMANTYLETHYLOXY-3-MORPHOLINO-2-PROPANOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
  申请人：Zagorii, Gleb Vladimirovich

  公开号：EP2905022A1

  公开（公告）日：2015-08-12

  A pharmaceutical composition for parenteral use comprising 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof within the concentration range of 3-100 mg/ml for treatment of cardiovascular pathology.

  一种肠外用药物组合物，包含 1-金刚烷酰氧基-3-吗啉基-2-丙醇或其药学上可接受的盐，浓度范围为 3-100 毫克/毫升，用于治疗心血管疾病。
• USE OF 1-ADAMANTYLETHYLOXY-3-MORPHOLINO-2-PROPANOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PHARMACEUTICAL COMPOSITIONS AS A NEURORETINAL PROTECTOR
  申请人：Zagorii, Gleb Vladimirovich

  公开号：EP2905025A1

  公开（公告）日：2015-08-12

  The use of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof in pharmaceutical compositions as a neuroretinoprotector within the concentration range of 3-100 mg/ml for treatment of neuroretinodegenerative diseases of various geneses.

  1-adamantylethyloxy-3-morpholino-2-propanol 或其药学上可接受的盐在药物组合物中用作神经视网膜保护剂，浓度范围为 3-100 mg/ml，用于治疗各种基因的神经视网膜退行性疾病。
• PHARMACEUTICAL COMPOSITION OF 1-ADAMANTYLETHYLOXY-3-MORPHOLINO-2-PROPANOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF CEREBROVASCULAR DISEASE AND NEURODEGENERATIVE DISEASES OF THE CENTRAL NERVOUS SYSTEM
  申请人：Zagorii, Gleb Vladimirovich

  公开号：EP2905017B1

  公开（公告）日：2018-06-20
• USE OF 1-ADAMANTYLETHYLOXY-3-MORPHOLINO-2-PROPANOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PHARMACEUTICAL COMPOSITIONS AS A NEURORETINAL PROTECTOR
  申请人：ZAGORII Gleb Vladimirovich

  公开号：US20150265623A1

  公开（公告）日：2015-09-24

  The use of 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml in pharmaceutical compositions for parenteral administration in the treatment of degenerative neuroretinal diseases of various geneses.
• US9333207B2
  申请人：——

  公开号：US9333207B2

  公开（公告）日：2016-05-10